Recently, we demonstrated that low expression levels of TGFBR2 mRNA are associated with more aggressive prostate cancer phenotypes and with a higher risk to develop resistance to anticancer treatment [38]. This evidence concerns the gene TGFBR2 and Familial prostate cancer.